Return to homepagePandemic Pact

Corona virus-specific antibody tests to assess immunity in the population

Grant number: unknown

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    2020
    2020

  • Known Financial Commitments (USD)

    $53,955

  • Funder

    WWTF Austria

  • Principal Investigator

    Wilhem Gerner

  • Research Location

    Austria

  • Lead Research Institution

    University of Veterinary Medicine, Vienna

  • Research Priority Alignment

    N/A

  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Diagnostics

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

The rapid spread of COVID 19 infections suggests that many infections caused by SARS-CoV-2 cause little or no clinical symptoms. However, infection with the virus can trigger an immune response in such patients as well. The rapid identification of SARS-CoV-2 specific antibodies by an ELISA test would be of great value in identifying medical personnel who have already built an immune response against SARS-CoV-2, as these individuals are working with COVID 19 Patients may be protected from SARS-CoV-2. In addition, such a test would be extremely valuable to monitor the spread of antibodies to SARS-CoV-2 in the population and to aid in assessing herd immunity. With regard to the further planning of the protective measures currently in place, this information would be an extremely important contribution. The structure of an antibody test for the identification of SARS-CoV-2-specific antibodies in human serum was recently described. Based on this information, we want to establish an ELISA test for the detection of anti-SARS-CoV-2 antibodies in human samples.